Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664389 | 0.94 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6836550 | 0.94 | ADRB2 (0.89) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4435801 | 0.93 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4553648 | 0.93 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4431300 | 0.93 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4430206 | 0.92 | ADRB3 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6664332 | 0.92 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6661634 | 0.92 | ADRB3 (0.89) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6684421 | 0.92 | ADRB3 (0.84) | ADRB2ADRB3ADRB1 | |
| SCHEMBL6663555 | 0.90 | ADRB3 (0.87) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004014850-A2 | SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004014850-A2 | SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | TACR1, GRPR, BDKRB1 | ADRB2 192/4885ADRB3 324/4885ADRB1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.